Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetics Generation AdvancementROCO:4160 -1.20%70 Gross Margin % is 42.57% as of Dec. 2025, which is 9% above its 10-year median of 38.97. GuruFocus rates ROCO:4160 with a GF Score™ of 70/100 and a GF Value™ of NT$51.35 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, Genetics Generation Advancement ranks worse than 60% on this metric.
ROCO:4160's Gross Margin % is ranked worse than 60% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.31
vs ROCO:4160: 41.53
Genetics Generation Advancement had a gross margin of 42.57% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Genetics Generation Advancement had a gross margin of 42.57% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Genetics Generation Advancement Gross Margin % Related Terms
Genetics Generation Advancement Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4160 vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Genetics Generation Advancement's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Genetics Generation Advancement (ROCO:4160) has a Gross Margin % of 42.57% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Genetics Generation Advancement and its competitors. This is near median its historical median of 38.97. Over the past decade, Genetics Generation Advancement's Gross Margin % has ranged from 26.58 to 42.31. According to the industry distribution chart, Genetics Generation Advancement ranks #117 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 60%.
Is Genetics Generation Advancement's Gross Margin % too high?
Genetics Generation Advancement's current Gross Margin % of 42.57% is near median its 10-year median of 38.97. Over the past 10 years, this metric has ranged from a low of 26.58 to a high of 42.31. The Medical Diagnostics & Research industry median Gross Margin % is 51.31. Genetics Generation Advancement's value of 42.57% is 17% below this industry median. Based on the distribution chart, Genetics Generation Advancement ranks #117 out of 195 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Genetics Generation Advancement has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genetics Generation Advancement ranks #117 out of 195 companies for Gross Margin %. This places Genetics Generation Advancement in the lower half of its industry. The industry median Gross Margin % is 51.31. Genetics Generation Advancement's value of 42.57% is 17% below this benchmark. Historically, Genetics Generation Advancement's own Gross Margin % has ranged from 26.58 to 42.31 over the past decade. While the company's 10-year median is 38.97 vs. the industry median of 51.31, Genetics Generation Advancement has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.31, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genetics Generation Advancement's current Gross Margin % of 42.57% is 17% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Genetics Generation Advancement and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genetics Generation Advancement's current Gross Margin % is 42.57%, which is near median its own 10-year median of 38.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.35, compared to a current price of NT$41.15 — trading 19.9% below its estimated fair value. The current Gross Margin % is 42.57%, which is near median its 10-year median of 38.97 and 17% below the Medical Diagnostics & Research industry median of 51.31. Genetics Generation Advancement's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current Gross Margin % is 42.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?
Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued.
The current stock price of NT$41.15 is trading 19.9% below its estimated GF Value™ of NT$51.35.
GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.
Key valuation signals for ROCO:4160:
Gross Margin %: 42.57% (near median its 10-year median of 38.97)
GF Value™: NT$51.35 vs. price of NT$41.15 (19.9% below fair value)
Industry Position: 17% below the Medical Diagnostics & Research median (#117 of 195)
No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetics Generation Advancement Business Description
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
70GF Score
Get the complete analysis for ROCO:4160
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4160 has been successfully added to your 
